Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

L-DOS 47

Next Previous
X
Search
Drug Profile

L-DOS 47

Alternative Names: L-DOS47

Latest Information Update: 12 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helix BioPharma
  • Developer Helix BioPharma; University Hospital Tuebingen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Ureases
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Lung cancer; Non-small cell lung cancer
  • Phase I/II Pancreatic cancer
  • Preclinical Cancer

Most Recent Events

  • 11 Oct 2023 Pharmacodynamics data from preclinical studies in Cancer presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC - 2023)
  • 12 Dec 2022 Preclinical trials in Cancer in Canada (IV)
  • 26 Oct 2022 Pharmacodynamics data from preclinical studies in Pancreatic cancer presented at 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top